Engineered immune cells take on stomach cancer in early trial

NCT ID NCT07509008

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment for stomach cancer that has spread to the lining of the abdomen. Ten adults will receive specially engineered immune cells (NK cells) infused directly into the abdomen, along with standard chemotherapy drugs. The main goals are to find a safe dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

engineered natural killer (NK) cells

What this could lead to

If it works, this could point toward a new treatment option for stomach cancer that has spread to the abdomen.

What could go wrong

This is a very early, small trial (10 people) focused on safety and dosing. The treatment may not work or could cause serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER, METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UT MD Anderson

    Houston, Texas, 77030, United States

    Contact

    Contact